LALPATHLAB Dr. Lal Path Labs Q4 FY25 results (Jan–Mar 2025) and concall
Dr Lal Pathlabs delivered a steady Q4 FY25 with 10.5% revenue growth, primarily driven by volume increases and a shift toward higher-value bundled tests (SwasthFit). While margins remained strong at 28.1%, management signaled a slight moderation to 27% for FY26 to fund aggressive network expansion and digital initiatives. The integration of Suburban Diagnostics faced temporary headwinds due to IT transitions but is expected to recover in the coming quarters.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 660 | 597 | 603 |
| EBITDA | 202 | 154 | 169 |
| Net profit | 131 | 98 | 156 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
